METOPROLOL SUCCINATE ( DrugBank: Metoprolol )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
57特発性拡張型心筋症1
58肥大型心筋症3
113筋ジストロフィー2
193プラダー・ウィリ症候群3

57. 特発性拡張型心筋症


臨床試験数 : 12 薬物数 : 25 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 34
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01798992
(ClinicalTrials.gov)
September 200022/2/2013Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartBeta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human HeartIdiopathic Dilated CardiomyopathyDrug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosinUniversity of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZenecaCompleted18 YearsN/AAll56Phase 4United States

58. 肥大型心筋症


臨床試験数 : 119 薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-IIR-17013661
2018-10-102017-12-03Effect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trialEffect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trial Hypertrophic cardiomyopathyExperimental group:Metoprolol Succinate Sustained-release Tablets combined with candesartan treatment;Control group:Metoprolol Succinate Sustained-release Tablets monotherapy;The First Affiliated Hospital, Sun Yat-sen UniversityNULLRecruiting1865BothExperimental group:130;Control group:130;4 (Phase 4 study)China
2NCT03532802
(ClinicalTrials.gov)
May 1, 201819/4/2018The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.Hypertrophic CardiomyopathyDrug: Metoprolol Succinate;Drug: Placebo oral capsuleSteen Hvitfeldt PoulsenNULLCompleted18 YearsN/AAll30Phase 2Denmark
3EUCTR2017-004478-32-DK
(EUCTR)
10/01/201814/12/2017The effect of metoprolol in hypertrophic obstructive cardiomyopathyThe effect of metoprolol on myocardial function, hemodynamics and heart failure symptoms in patients with hypertrophic obstructive cardiomyopathy - TEMPO Hypertrophic obstructive cardiomyopathy
MedDRA version: 20.0;Level: LLT;Classification code 10020876;Term: Hypertrophic obstructive cardiomyopathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Metoprololsuccinat
INN or Proposed INN: metoprololsuccinat
Other descriptive name: METOPROLOL SUCCINATE
Aarhus University HospitalNULLNot RecruitingFemale: yes
Male: yes
32Phase 2Denmark

113. 筋ジストロフィー


臨床試験数 : 622 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004901-29-PL
(EUCTR)
01/06/202120/01/2021Metoprolol Safety and Efficacy in the Prevention of Cardiomyopathy in Patients with Duchenne Muscular Dystrophy (DMD).The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-16 years. A randomized, double-blind, placebo controlledstudy. - MeDMD Duchenne muscular dystrophyCardiomyopathyTachycardia
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Betaloc ZOK 25, 23,75 mg
INN or Proposed INN: Metoprolol
Other descriptive name: METOPROLOL SUCCINATE
Trade Name: Betaloc ZOK 100, 95 mg
INN or Proposed INN: Metoprolol
Other descriptive name: METOPROLOL SUCCINATE
Medical University of GdanskNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
144Phase 3Poland
2EUCTR2009-009871-36-DE
(EUCTR)
06/08/2009Study within children with Duchenne Muscular DystrophyEffect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: EnalHexal®, 5 mg
INN or Proposed INN: ENALAPRIL
Trade Name: EnaHexal®, 10mg
INN or Proposed INN: ENALAPRIL
Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Friedrich- Alexander- Universität Erlangen NürnbergNULLNot RecruitingFemale: no
Male: yes
Germany

193. プラダー・ウィリ症候群


臨床試験数 : 111 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000127-12-SE
(EUCTR)
03/01/202208/11/2021A 16-week phase 2b, double-blind, placebo-controlled, Multi center, dose finding safety and efficacy study to evaluate overall safety and tolerability of Tesomet ( tesofensine and metoprolol) in subjects with Prader-Willi Syndrome, and with an optional 38-week open-label extensionA Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects with Prader-Willi Syndrome Prader-Willi Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Tesomet
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE CITRATE
INN or Proposed INN: Metoprolol
Other descriptive name: METOPROLOL SUCCINATE (PH. EUR.)
Product Name: Tesomet
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE CITRATE
INN or Proposed INN: Metoprolol
Other descriptive name: METOPROLOL SUCCINATE (PH. EUR.)
Product Name: Tesomet
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE CITRATE
INN or Proposed INN: Metoprolol
Other descriptive name: METOPROLOL SUCCINATE (PH. EUR.)
Saniona A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2France;United States;Spain;Belgium;Ireland;Australia;United Kingdom;New Zealand;Italy;Sweden
2EUCTR2016-003694-18-CZ
(EUCTR)
18/01/201704/10/2016Safety and efficacy of tesofensine/metoprolol in subjects with Prader-Willi syndromeA double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS) Second 12 weeks open label extension Prader Willi syndrome (PWS)
MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Tesofensine
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE
Trade Name: Metoprololsuccinat ”Orion” 25mg
INN or Proposed INN: metoprolol
Other descriptive name: METOPROLOL SUCCINATE
Saniona A/SNULLNot RecruitingFemale: yes
Male: yes
35Phase 2Hungary;Czech Republic
3EUCTR2016-003694-18-HU
(EUCTR)
22/12/201613/10/2016Safety and efficacy of tesofensine/metoprolol in subjects with Prader-Willi syndromeA double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS) A 12 weeks open label extension Prader Willi syndrome (PWS)
MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Tesofensine
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE
Trade Name: Metoprololsuccinat Orion 25mg
INN or Proposed INN: metoprolol
Other descriptive name: METOPROLOL SUCCINATE
Saniona A/SNULLNot Recruiting Female: yes
Male: yes
35 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noCzech Republic;Hungary